Facebook Linkedin RSS Twitter Youtube
Home 2023

Bristol-Myers Squibb

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market
Bioprocessing

Meeting on the Mesa: How to Bring Cell and Gene Therapies to Market

Jonathan D Grinstein, PhD -
0
BMS Expands Its Cancer Portfolio with Up-to-$5.8B Mirati Purchase
Cancer

BMS Expands Its Cancer Portfolio with Up-to-$5.8B Mirati Purchase

Alex Philippidis -
0
Downstream Trends and Challenges
Bioprocessing

Downstream Trends and Challenges

John Sterling -
0
Schrödinger’s Equation: Physics + Machine Learning = Drug Discovery
Artificial Intelligence

Schrödinger’s Equation: Physics + Machine Learning = Drug Discovery

Alex Philippidis -
0
Protein Knockdowns May Obviate Genetic Knockouts
Drug Discovery

Protein Knockdowns May Obviate Genetic Knockouts

Jonathan D Grinstein, PhD -
0
BMS Collaboration Paying Off for Exscientia
Artificial Intelligence

BMS Collaboration Paying Off for Exscientia

Alex Philippidis -
0
EY Eyes Comeback for Biopharma M&A
GEN Edge

EY Eyes Comeback for Biopharma M&A

Alex Philippidis -
1
Double Dare: Exscientia Expands AI Platform into Antibody Design
Artificial Intelligence

Double Dare: Exscientia Expands AI Platform into Antibody Design

Alex Philippidis -
0
Biopharma Facility Planning Improves with Monte Carlo Simulation Modeling
Bioprocessing

Biopharma Facility Planning Improves with Monte Carlo Simulation Modeling

John Sterling -
0
Cancer I-O Pioneer, Executive Target Immune Disruption with $65M Startup
Cancer

Cancer I-O Pioneer, Executive Target Immune Disruption with $65M Startup

Alex Philippidis -
0
123...27Page 1 of 27
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.